Onco-Innovation collaborations awarded from pump prime call
Last month, the Onco-Innovation Programme — part of the CRUK Cambridge Centre and managed by our own Dr Rebecca Harris — launched a new rapid response data analysis pump prime call. This exciting new call was designed to seek collaborative project proposals from CRUK...
Milner collaboration targets RNA-modifying enzymes as promising anti-cancer strategy
Work at the Milner Therapeutics Institute by Director Tony Kouzarides and Kostas Tzelepis in collaboration with Storm Therapeutics has made a promising step towards developing a new drug for treating acute myeloid leukaemia. In a paper published today in Nature,...
Autophagy targets in neurodegeneration
We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in neurodegeneration. This is the first such project to bring together multiple academic groups across the University and...
Milner Consortium reaches 10
We are excited to announce that two new pharma partners — Eli Lilly and Company and Bristol Myers Squibb — have joined the Milner Consortium in the past month. Now with ten pharma partners and three academic partners, this has become one of the largest cross-sector...